Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Huntington National Bank

Huntington National Bank lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 40.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,109 shares of the company’s stock after acquiring an additional 2,921 shares during the period. Huntington National Bank’s holdings in Teva Pharmaceutical Industries were worth $169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ion Asset Management Ltd. grew its stake in Teva Pharmaceutical Industries by 6.5% during the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after purchasing an additional 2,383,500 shares during the last quarter. Phoenix Financial Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 31.7% during the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after buying an additional 11,334,780 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Teva Pharmaceutical Industries by 2.8% in the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company’s stock worth $448,640,000 after buying an additional 808,074 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock worth $480,768,000 after buying an additional 2,350,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TEVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Stock Down 1.9%

TEVA opened at $24.01 on Friday. The company has a fifty day moving average of $19.74 and a two-hundred day moving average of $17.83. The stock has a market capitalization of $27.53 billion, a price-to-earnings ratio of -150.03, a PEG ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.48 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the firm earned $0.69 EPS. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.